Close Menu

NEW YORK – Infectious disease testing firm MeMed and diagnostics company DiaSorin announced on Tuesday a licensing agreement giving DiaSorin the right to commercialize MeMed's BV test for distinguishing between bacterial and viral infections.

Under the agreement, Saluggia, Italy-based DiaSorin will commercialize the test for use on its Liaison analyzer platform, which will make it available on the more than 5,000 LIASON systems installed globally.

Haifa, Israel-based MeMed will also continue to sell the test for use on its own point-of-care platform, the MeMed Key.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.